Streetbeat News

Analyst Ratings

LSTA

Lisata Therapeutics reported Q2 losses of $(0.50) per share, beating the analyst consensus estimate of $(0.70) by 28.57%. This is a 69.51% increase over losses of $(1.64) per share from the same period last year.

Portfolio Pulse from bharat@benzinga.com

August 14, 2023 | 8:18 pm

LMT

A significant investor has taken a bearish stance on Lockheed Martin (NYSE:LMT), with 75% of recent trades being bearish. The price target range for the company over the last three months has been $420.0 to $500.0. The current price of LMT is down -0.89% at $450.01. Analysts have mixed opinions, with Morgan Stanley downgrading its action to Equal-Weight with a price target of $532, while Citigroup maintains a Buy rating with a price target of $555.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 8:16 pm

TGAN

Transphorm (NASDAQ:TGAN) reported Q1 losses of $(0.08) per share, beating the analyst consensus estimate of $(0.11) by 27.27%. However, the company's quarterly sales of $5.88 million missed the analyst consensus estimate of $5.92 million by 0.63%. This represents a 14.10% increase over sales of $5.16 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:16 pm

TCON

TRACON Pharma reported Q2 losses of $0.20 per share, beating the analyst consensus estimate of $0.36 by 44.44%. This is a 35.48% increase over losses from the same period last year. The company also reported $9.00 million in sales this quarter.

Portfolio Pulse from bharat@benzinga.com

August 14, 2023 | 8:15 pm

BEEM

Beam Global (NASDAQ:BEEM) reported Q2 losses of $(0.32) per share, beating the analyst consensus estimate of $(0.34) by 5.88%. This is a 14.29% decrease over losses from the same period last year. The company also reported quarterly sales of $17.82 million, beating the analyst consensus estimate of $14.40 million by 23.74%. This is a 379.26% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:14 pm

GVP

GSE Systems (NASDAQ:GVP) reported Q2 losses of $(0.06) per share, beating the analyst consensus estimate of $(0.11) by 45.45%. The company also reported quarterly sales of $12.39 million, surpassing the analyst consensus estimate of $11.47 million by 7.99%. However, this represents a 2.81% decrease over sales of $12.74 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:13 pm

CMPO

CompoSecure (NASDAQ:CMPO) reported Q2 earnings of $0.25 per share, in line with analyst consensus. However, this is a 51.92% decrease from the same period last year. The company's quarterly sales of $98.53M missed the analyst consensus estimate of $100.69M by 2.15%, but it's a 1.37% increase from the same period last year.

Portfolio Pulse from totan@benzinga.com

August 14, 2023 | 8:13 pm

INVO

INVO Bioscience reported Q2 losses of $(3.06) per share, beating the analyst consensus estimate of $(4.20) by 27.14%. However, the company's quarterly sales of $315.90K missed the analyst consensus estimate of $2.96M by 89.33%. This represents a 1230.43% increase in losses and a 116.17% increase in sales compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

August 14, 2023 | 8:08 pm

SLGC

SomaLogic (NASDAQ:SLGC) reported Q2 earnings per share of $(0.13), beating the analyst consensus estimate of $(0.16) by 18.75%. The company's quarterly sales were $20.47 million, surpassing the analyst consensus estimate of $19.82 million by 3.27%. This represents a 44.71% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:07 pm

VTSI

VirTra reported Q2 earnings of $0.09 per share, beating the analyst consensus estimate of $0.08 by 12.5%. The company also reported quarterly sales of $10.30 million, surpassing the analyst consensus estimate of $7.99 million by 28.91%. Both earnings and sales have increased compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:06 pm